Medical/Pharmaceuticals
Professor Luo Min Appointed as Chairman of Spine Neurocardiology Interdisciplinary Professional Committee in China to Promote Development of Innovative Heart Disease Treatments
BEIJING, Sept. 23, 2024 /PRNewswire/ -- Professor Luo Min, Doctor of Medicine (MD), from Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, was recently appointed as the Chairman of the National Association of Health Industry and Enterprise Management (NAHIE...
2024-09-23 15:06
1940
Meihua International Medical Technologies Co., Limited Reports Unaudited 2024 First Half Financial Results
YANGZHOU, China, Sept. 20, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today reported its unaudited ...
2024-09-21 05:30
8115
Biosyngen Best-in-Class Next-Generation Tumor-Infiltrating Lymphocyte (TIL) Technology Debuts on ESMO 2024 Annual Meeting
BARCELONA, Spain, Sept. 20, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place fromSeptember 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading...
2024-09-20 20:30
2863
Kangpu Completed Bridging Clinical Study of KPG-818 in China
HEFEI, China, Sept. 20, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals, a clinical-stage company based inHefei, China, announced today that the Company has successfully completed a bridging clinical study of KPG-818 in healthy subjects inChina. The randomized, double-blind, placebo-controlled,...
2024-09-20 20:00
2930
CD (Suzhou) Biopharma Announces FDA Clearance for Phase I Clinical Trial of CD-001
SUZHOU, China, Sept. 20, 2024 /PRNewswire/ -- CD (Suzhou) Biopharma
2024-09-20 16:28
2394
Biosyngen Presents Pioneering"Conditional Activation + Armor Enhancement" SUPER-T technology at ESMO 2024
BARCELONA, Spain, Sept. 19, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place fromSeptember 13 to 17 in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading...
2024-09-19 20:30
2097
NUS scientists discover novel approach to rejuvenate aged egg cells
Groundbreaking findings provide a proof-of-concept development of a
non-invasive cell-based method to improve the quality of eggs from older
females for IVF
SINGAPORE, Sept. 19, 2024 /PRNewswire/ -- Researchers from the Mechanobiology
Institute
2024-09-19 18:28
2796
MGI Tech partners with Dasa to enhance health diagnosis with genetic sequencing in Brazil
New technologies will contribute to performing genetic tests to diagnose cancers, rare diseases and other diseases with greater precision, advancing personalized medicine in the country SÃO PAULO, Brazil, Sept. 18, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building ...
2024-09-19 11:05
2384
Best Poster of ESMO 2024! Abbisko Announces Updated Clinical Data of Irpagratinib in HCC
SHANGHAI, Sept. 18, 2024 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) is excited to announce the receipt of the ESMO 2024 Best Poster Award on September 16, 2024. The award was received for the presentation titled "Updated Safety and Efficacy of Irpagratinib (ABSK011) in advanced hepatocell...
2024-09-19 09:00
6667
Insilico Medicine Reports Positive Phase IIa Results for ISM001-055, a Novel First-in-Class Drug Treatment for Idiopathic Pulmonary Fibrosis (IPF) Designed Using Generative AI
* ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK- interacting kinase) and has progressed through Phase IIa clinical testing. * Preliminary results from this 12-week study demonstrated that ISM001-055 possesses a favorable safety profile and dos...
2024-09-18 21:30
2159
Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress
BARCELONA, Spain, Sept. 18, 2024 /PRNewswire/ -- The highly anticipated 2024 European Society for Medical Oncology (ESMO) Annual Congress has taken place in Barcelona, Spain. As one of the most influential annual gatherings in oncology, this congress brings together leading cancer experts and rese...
2024-09-18 18:18
2941
TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging
HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and gr...
2024-09-18 16:00
3078
AI Plus Clinic Tamaplaza Enhances System to Provide Rapid Diagnosis and Peace of Mind with Remote Robots Starting September 2024
YOKOHAMA, Japan, Sept. 18, 2024 /PRNewswire/ -- - New System Integrates AI Technology and Home Healthcare Launched in July 2024 - AI Plus Clinic Tamaplaza, based in Aoba-ku, Yokohama, Kanagawa Prefecture, operating under Kouetsukai Medical Corporation, has announced a new medical system integra...
2024-09-18 14:00
1919
inHearing Technology Inc. Announced the Acquisition of Intricon's Hearing Health Business
ST. PAUL, Minn., Sept. 17, 2024 /PRNewswire/ -- inHearing Technology Inc., a
wholly-owned subsidiary ofHuizhou Jinghao Medical Technology Co., Ltd.,
announced onSeptember 11, 2024, the acquisition of Intricon's Hearing Health
Business.
2024-09-18 10:27
3522
Senhwa Biosciences Announces IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI
TAIPEI and SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), , a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that an Investigational New Drug (IND) application for Pidnarulex ...
2024-09-18 10:06
3182
Breakthrough in Long COVID: An investigator-initiated trial (IIT) with Hyundai Bioscience's Xafty by UCSD
SAN DIEGO, Sept. 17, 2024 /PRNewswire/ -- Hyundai Bioscience USA announced that it has signed an MOU with theUniversity of California San Diego (UCSD) to conduct an investigator-initiated trial to evaluate the efficacy of Xafty®, a niclosamide-based antiviral developed by its Korean headquarters,...
2024-09-18 09:26
3930
Datasea's New 5G AI Multimodal Agreements Have Already Generated $9.0 Million of 5G-AI Services
Agreements Boost Fiscal 2025 Revenue and Expand Datasea's 5G Application Market Positioning inChina BEIJING, Sept. 17, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada-based company focused on innovative high-tech acoustics and 5G-Artificial Intelligence ("A...
2024-09-17 21:45
2797
See-Mode Technologies Receives FDA Clearance for Thyroid Ultrasound AI Analysis and Reporting Software
MELBOURNE, Australia, Sept. 17, 2024 /PRNewswire/ -- See-Mode Technologies, a global innovator in AI for ultrasound imaging, today announced the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their thyroid ultrasound analysis and reporting software. See-Mode's A...
2024-09-17 20:00
2715
Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics
Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...
2024-09-17 15:47
3138
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. ...
2024-09-17 00:01
2427
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 291 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8629
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
7947
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7041
